ENDPOINTS NEWS32 分钟
Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin
AbbVie becomes an obesity contender as it partners with Danish biotech Gubra in $350M upfront deal for amylin analog GUBamy, ...